QQ客服 官方微博 反馈留言

	LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung
	Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Li, Wei; Hou, Mei; Shi, Jian Hua; Lee, Kye Young
刊名	EUROPEAN RESPIRATORY JOURNAL
	2013
卷号	42
ISSN号	0903-1936
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3548601
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Wu, Yi-Long,Zhou, Caicun,Hu, Cheng-Ping,et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung[J]. EUROPEAN RESPIRATORY JOURNAL,2013,42.
APA	Wu, Yi-Long.,Zhou, Caicun.,Hu, Cheng-Ping.,Feng, Jifeng.,Lu, Shun.,...&Geater, Sarayut L..(2013).LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung.EUROPEAN RESPIRATORY JOURNAL,42.
MLA	Wu, Yi-Long,et al."LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFRM plus ) advanced adenocarcinoma of the lung".EUROPEAN RESPIRATORY JOURNAL 42(2013).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。